EE200000346A - Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidel - Google Patents
Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidelInfo
- Publication number
- EE200000346A EE200000346A EEP200000346A EEP200000346A EE200000346A EE 200000346 A EE200000346 A EE 200000346A EE P200000346 A EEP200000346 A EE P200000346A EE P200000346 A EEP200000346 A EE P200000346A EE 200000346 A EE200000346 A EE 200000346A
- Authority
- EE
- Estonia
- Prior art keywords
- treatment
- men
- dyssynergy
- urinary
- study
- Prior art date
Links
- 229940122815 Aromatase inhibitor Drugs 0.000 title abstract 2
- 239000003098 androgen Substances 0.000 title abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 2
- 230000003247 decreasing effect Effects 0.000 title abstract 2
- 239000000262 estrogen Substances 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010003591 Ataxia Diseases 0.000 title 1
- 241000700159 Rattus Species 0.000 title 1
- 230000002485 urinary effect Effects 0.000 title 1
- 210000005070 sphincter Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,447 US5972921A (en) | 1997-12-12 | 1997-12-12 | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| PCT/FI1998/000954 WO1999030708A2 (en) | 1997-12-12 | 1998-12-09 | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200000346A true EE200000346A (et) | 2001-10-15 |
Family
ID=25535123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200000346A EE200000346A (et) | 1997-12-12 | 1998-12-09 | Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidel |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5972921A (et) |
| EP (1) | EP1043993B1 (et) |
| JP (1) | JP2002508322A (et) |
| KR (1) | KR20010032909A (et) |
| CN (1) | CN1281361A (et) |
| AT (1) | ATE235904T1 (et) |
| AU (1) | AU743196B2 (et) |
| BR (1) | BR9813534A (et) |
| CA (1) | CA2312347A1 (et) |
| DE (1) | DE69813025T2 (et) |
| EE (1) | EE200000346A (et) |
| ES (1) | ES2191358T3 (et) |
| HU (1) | HUP0100762A3 (et) |
| NO (1) | NO20002960L (et) |
| NZ (1) | NZ504632A (et) |
| PL (1) | PL341653A1 (et) |
| WO (1) | WO1999030708A2 (et) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| MXPA02001547A (es) * | 1999-08-13 | 2002-07-02 | Wieland Heinrich | Extractos de glicinas de soya e inhibidores de aromatasa para afectar positivamente colageno. |
| WO2001076574A2 (en) * | 2000-04-12 | 2001-10-18 | Novartis Ag | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| US20030083342A1 (en) * | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| FI20010905A0 (fi) * | 2001-05-02 | 2001-05-02 | Vetcare Oy | Uusi eläinlääke |
| US6607755B2 (en) * | 2001-06-21 | 2003-08-19 | Michael Donald Farley | Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios |
| US6931276B2 (en) * | 2002-04-29 | 2005-08-16 | Tomi Streng | Method and device for use in micturition studies |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| CA2535944A1 (en) * | 2003-08-22 | 2005-03-03 | University Of Virginia Patent Foundation | Blockade of mtor to prevent a hormonal adaptive response |
| RU2480207C2 (ru) * | 2006-05-22 | 2013-04-27 | Хормос Медикал Лтд. | Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы |
| KR20140071358A (ko) * | 2011-09-08 | 2014-06-11 | 노파르티스 아게 | 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도 |
| CN102641502A (zh) * | 2012-04-25 | 2012-08-22 | 中国农业大学 | 芳香酶抑制剂的新用途 |
| US20170095520A1 (en) * | 2014-03-21 | 2017-04-06 | Dong Wha Pharm. Co., Ltd. | A composition for preventing, treating, and improving of voiding dysfunction comprising extract of Piper longum L. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2273704B (en) | 1992-12-16 | 1997-01-22 | Orion Yhtymae Oy | Triazolyl diaryl selective aromatase inhibiting compounds |
| DE4435368A1 (de) | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
-
1997
- 1997-12-12 US US08/989,447 patent/US5972921A/en not_active Expired - Fee Related
-
1998
- 1998-09-12 US US09/581,128 patent/US6316431B1/en not_active Expired - Lifetime
- 1998-12-09 EP EP98958935A patent/EP1043993B1/en not_active Expired - Lifetime
- 1998-12-09 DE DE69813025T patent/DE69813025T2/de not_active Expired - Lifetime
- 1998-12-09 PL PL98341653A patent/PL341653A1/xx unknown
- 1998-12-09 CN CN98812074A patent/CN1281361A/zh active Pending
- 1998-12-09 ES ES98958935T patent/ES2191358T3/es not_active Expired - Lifetime
- 1998-12-09 NZ NZ504632A patent/NZ504632A/en unknown
- 1998-12-09 CA CA002312347A patent/CA2312347A1/en not_active Abandoned
- 1998-12-09 BR BR9813534-1A patent/BR9813534A/pt not_active IP Right Cessation
- 1998-12-09 AU AU14897/99A patent/AU743196B2/en not_active Ceased
- 1998-12-09 EE EEP200000346A patent/EE200000346A/et unknown
- 1998-12-09 WO PCT/FI1998/000954 patent/WO1999030708A2/en not_active Ceased
- 1998-12-09 JP JP2000538691A patent/JP2002508322A/ja active Pending
- 1998-12-09 AT AT98958935T patent/ATE235904T1/de not_active IP Right Cessation
- 1998-12-09 KR KR1020007006244A patent/KR20010032909A/ko not_active Withdrawn
- 1998-12-09 HU HU0100762A patent/HUP0100762A3/hu unknown
-
2000
- 2000-06-09 NO NO20002960A patent/NO20002960L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0100762A3 (en) | 2002-12-28 |
| BR9813534A (pt) | 2000-11-14 |
| CN1281361A (zh) | 2001-01-24 |
| AU1489799A (en) | 1999-07-05 |
| US5972921A (en) | 1999-10-26 |
| JP2002508322A (ja) | 2002-03-19 |
| DE69813025T2 (de) | 2004-01-15 |
| EP1043993B1 (en) | 2003-04-02 |
| NO20002960L (no) | 2000-08-14 |
| PL341653A1 (en) | 2001-04-23 |
| KR20010032909A (ko) | 2001-04-25 |
| WO1999030708A3 (en) | 1999-08-19 |
| NZ504632A (en) | 2001-10-26 |
| CA2312347A1 (en) | 1999-06-24 |
| ATE235904T1 (de) | 2003-04-15 |
| US6316431B1 (en) | 2001-11-13 |
| EP1043993A2 (en) | 2000-10-18 |
| ES2191358T3 (es) | 2003-09-01 |
| NO20002960D0 (no) | 2000-06-09 |
| WO1999030708A2 (en) | 1999-06-24 |
| AU743196B2 (en) | 2002-01-24 |
| HUP0100762A2 (hu) | 2001-08-28 |
| DE69813025D1 (de) | 2003-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200000346A (et) | Aromataasi inhibiitori kasutamine alanenud androgeeni/östrogeeni suhte ja kuseväljutaja/kusitisulguri düssünergia ravimiseks meestel ning düssünergia uurimise meetod isastel rottidel | |
| AU6093101A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| ATE370730T1 (de) | Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung | |
| AU8536701A (en) | Method of increasing testosterone and related steroid concentrations in women | |
| MXPA02010149A (es) | Composiciones de compuestos bioquimicos comprendidos en el metabolismo de bioenergia de las celulas y metodo de uso.. | |
| NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
| WO2002058706A3 (en) | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy | |
| AU2001266133A1 (en) | Composition, in particular cosmetic, containing dhea and/or a chemical or biological precursor or derivative thereof, and a metalloproteinase inhibitor | |
| EP1009755A4 (en) | STEROID SULFATASE INHIBITORS AND METHODS OF PRODUCING AND USING THE SAME | |
| PT771217E (pt) | Formas faramceuticas solidas clatratos da hormona sexual esteroide etinilestradiol | |
| EP1230952A3 (en) | Combinations of estrogen and progestogen for preventing and treating skin aging | |
| WO2002019982A3 (en) | Cosmetic composition and method for reducing or preventing wrinkling | |
| AU2001251730A1 (en) | Polybutadiene and polyisoprene based theremosetting compositions and method of manufacture | |
| AU6030999A (en) | Method of delivering therapeutic agents to the urethra and an urethral suppository | |
| MXPA04003977A (es) | Baja concentracion de peroxido para tratamiento o prevencion de infecciones vaginales. | |
| FR2791885B1 (fr) | Procede de teinture d'oxydation utilisant un cetose a titre d'agent reducteur et une laccase a titre d'agent oxydant | |
| MXPA02009744A (es) | Uso de fulvestrant en el tratamiento de cancer resistente de mama. | |
| DE60017281D1 (de) | Nomegestrol acetat und estrogen enthaltende zusammensetzung und ihre verwendung | |
| NO20053626L (no) | Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose | |
| DK0885005T3 (da) | Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd | |
| AU6567800A (en) | Substances and agents for positively influencing collagen | |
| AU7394601A (en) | Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability | |
| EP0841933A4 (en) | BOWMAN BIRK INHIBITOR COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES | |
| DK1347753T3 (da) | Topisk sammensætning og fremgangsmåde til behandling af urinstressinkontinens | |
| YU16403A (sh) | 4-halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja |